Morepen files first US drug application, eyes generic diabetes market

Reported by The Hindu BusinessLine (Economy), not nibnow. We are not the publisher of this story, only the source is.

FROM THE SOURCE

Morepen’s first US submission targets a late-stage entry into the global diabetes therapeutics market, leveraging a DPP-4 inhibitor with potential competitive timelines and regulatory milestones

Read the full story at The Hindu BusinessLine (Economy)